scholarly journals An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine)

1995 ◽  
Vol 311 (3) ◽  
pp. 867-872 ◽  
Author(s):  
R Wang ◽  
M E Klegerman ◽  
I Marsden ◽  
M Sinnott ◽  
M J Groves
Keyword(s):  
Bladder Cancer ◽  
Nmr Spectroscopy ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Water Extract ◽  
Two Dimensional ◽  
Methylation Analysis ◽  
S180 Sarcoma ◽  
Anti Tumour Activity ◽  
Tumour Activity

Tice substrain BCG is used clinically as an immunotherapeutic agent against superficial bladder cancer. A boiling-water extract of this BCG showed anti-tumour activity against a murine S180 sarcoma model and was fractionated into three fractions, A, B and C, by the use of Sephadex LH-20 chromatography. An anti-tumour glucan, PS1A1, was isolated from fraction PS1A with Sephadex G-75. The molecular mass of PS1A1 was between 65 and 87 kDa by Sephadex G-100 chromatography. The structure of PS1A1 was investigated by one- and two-dimensional NMR spectroscopy and methylation analysis and was demonstrated to be primarily 1-->6-alpha-linked glucose units. We postulate that the repeating unit is: [Formula: see text]

scholarly journals Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer

2012 ◽  
Vol 1 (3) ◽  
Author(s):  
Vincent Fradet ◽  
Christiane Gaudreau ◽  
Paul Perrotte ◽  
Jean Côté ◽  
Jean-Marie Paquin
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Granulomatous Hepatitis ◽  
Bacille Calmette Guerin ◽  
Systemic Complications ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Management Alternatives

Intravesical bacille Calmette-Guérin (BCG) therapy is the most effective treatmentfor high-risk superficial bladder cancer. Severe systemic complications are rare, but may occur in approximately 1% of cases. We report a severe complicationof intravesical BCG: a disseminated Mycobacterium bovis infectionwith biopsy-proven granulomatous hepatitis in a patient with bladder cancer. We also elaborate on the different management alternatives.

Mycobacterium bovis Cerebellar Abscess Following Treatment With Bacillus Calmette-Guérin

2016 ◽  
Vol 30 (3) ◽  
pp. 378-380 ◽  
Author(s):  
Mollie W. Sheron ◽  
Shannon L. Holt ◽  
Christopher W. Ingram
Keyword(s):  
Bladder Cancer ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Altered Mental Status ◽  
Bacillus Calmette Guerin ◽  
Systemic Complications ◽  
Cns Infections ◽  
Antituberculosis Therapy ◽  
Cerebellar Abscess ◽  
Bcg Therapy

Bacillus Calmette-Guérin (BCG) is a live, attenuated strain of Mycobacterium bovis that is used to treat superficial bladder cancer. Although its use is typically associated with only mild, localized side effects, rare systemic complications can occur. Disseminated mycobacterium infections after BCG therapy have been reported in over 30 cases; however, central nervous system (CNS) infections do not commonly occur. We report a 74-year-old male who developed a M. bovis cerebellar abscess after receiving intravesical BCG infusion for bladder cancer for less than 1 year. This patient was successfully treated with antituberculosis therapy and corticosteroids. This patient case demonstrates that early-onset M bovis CNS infections can occur after BCG therapy. Patients presenting with altered mental status while on BCG therapy should be evaluated for disseminated infections.

scholarly journals Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy

2019 ◽  
Vol 2019 (7) ◽  
Author(s):  
Sean Rezvani ◽  
Gerald Collins
Keyword(s):  
Bladder Cancer ◽  
Side Effects ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Rare Complication ◽  
Bacillus Calmette Guerin ◽  
Radiological Findings ◽  
Life Threatening ◽  
Established Treatment

Abstract BCG is a well-established treatment for superficial bladder cancer. Although usually well-tolerated, side effects can range from mild cystitis to life-threatening sepsis. Epididymitis is a rare complication of BCG, with only a handful of cases proven to be caused directly by Mycobacterium bovis. We describe one such case, along with radiological findings for this rare complication.

Host–Guest Inclusion System of Scutellarin with Polyamine-β-Cyclodextrin: Preparation, Characterisation, and Anti-cancer Activity

2015 ◽  
Vol 68 (6) ◽  
pp. 946 ◽  
Author(s):  
Xue Ma ◽  
Bo Yang ◽  
Yulin Zhao ◽  
Hudie Xie ◽  
Xiaoshun Gong
Keyword(s):  
Inclusion Complexation ◽  
Two Dimensional ◽  
X Ray Diffraction ◽  
Amino Groups ◽  
X Ray ◽  
Anti Tumour Activity ◽  
Anti Cancer ◽  
Tumour Activity ◽  
Cancer Activity ◽  
Scanning Electron

The inclusion complexation behaviours of scutellarin (SCU) with four polyamine-modified β-cyclodextrins (NH2-βCD, EN-βCD, DETA-βCD, and TETA-βCD; EN = ethylenediamine; DETA = diethylenetriamine; TETA = triethylenetetramine) have been investigated in both solution and solid state by photoluminescence spectroscopy, 1H and two-dimensional NMR spectroscopy, thermogravimetric analysis, X-ray diffraction, and scanning electron microscopy. The results showed that, with the increase in the number of amino groups, the hosts polyamine-modified β-cyclodextrins (NH2-βCD, EN-βCD, DETA-βCD, TETA-βCD) were able to solubilise SCU to higher levels than native β-CD (9.0 mg mL–1) up to 15.8, 20.4, 44.6, 50.7 mg mL–1 (calculated as SCU), respectively. Besides, the anti-tumour activity of SCU obviously increased after formation of the inclusion complexes. The SCU/CD complexes will be potentially useful for the design of a novel formulation of SCU for clinical treatment.

Sign in / Sign up

Export Citation Format

Share Document